Deferasirox Supplier in United Arab Emirates
DEFRATAJ — WHO-GMP Deferasirox dispersible tablets, supplied direct from the manufacturer to MOHAP-registered importers.
Supply & Market
The United Arab Emirates is a strategic GCC distribution hub for DEFRATAJ Deferasirox dispersible tablets, with onward re-export to Oman, Qatar, Bahrain and parts of East Africa through Jebel Ali Free Zone. Taj Pharma supports MOHAP-registered importers, DHA-licensed hospital pharmacies in Dubai, DOH-Abu-Dhabi tender supply, and the federally-funded Thalassemia Centre at Latifa Hospital — one of the region's largest paediatric thalassemia caseloads.
UAE prevalence of beta-thalassemia trait is among the highest in the GCC (estimated 8.5% carrier rate among Emirati nationals), supporting a steady demand for once-daily oral chelation therapy. Our team coordinates supply through the MOHAP eDrug portal, including SFDA-aligned bilingual labelling (Arabic/English), Halal-compliance declaration where applicable, and full UAE-format CTD dossier submission.
Logistics from Mumbai (JNPT) to Jebel Ali run on a 5–7 day transit lane with weekly sailings; air-freight via Dubai International is available for urgent hospital top-ups. Cold-chain is not required for dispersible tablets, but climatised reefer containers can be arranged on the Gulf summer route to keep ambient transit under 30°C as a precaution.
Supply Capability for the UAE
Taj Pharma supplies all DEFRATAJ strengths to UAE importers with full Arabic/English bilingual secondary packaging compliant to MOHAP Drug Department artwork requirements (Reg. No. placeholder, batch number, manufacturing/expiry dates in DD-MM-YYYY format, retail price imprint where required).
- Strengths shipped: 100 mg, 125 mg, 250 mg, 400 mg, 500 mg dispersible tablets
- Pack formats: bottles (30/60/100s), Alu-Alu blisters, hospital institutional packs (250s) for Latifa, SKMC, Tawam
- MOQ: 30,000 tablets per strength · flexible for hospital tender lots
- Lead time: 4 weeks ex-Mumbai · 5–7 days transit to Jebel Ali / Khalifa Port
- Re-export: Jebel Ali Free Zone bonded storage option for onward Oman / Qatar / Bahrain / Iraq dispatch
- Documentation: CoA, CoO, free-sale certificate, halal declaration, MOHAP Reg. No. linkage, batch protocol
- Tender lanes: SEHA (Abu Dhabi), DHA (Dubai), MoH-northern-emirates joint bid prepared on request
Regulatory Pathway in the UAE
Drug registration is administered by the UAE Ministry of Health and Prevention (MOHAP) — Drug Department, with parallel licensing recognition from the Department of Health Abu Dhabi (DOH-AD) and the Dubai Health Authority (DHA). Taj Pharma submits the dossier through the MOHAP eDrug portal in CTD format with UAE Module 1, including Arabic-translated SmPC and PIL, locally-tested bioequivalence data referencing the European reference product, and 12 months of Zone IVb long-term stability.
Standard MOHAP generic timeline is 9–12 months; pricing approval follows GCC Drug Pricing Committee guidance. We also coordinate Saudi-pathway re-references where the importer holds parallel SFDA registration. Pharmacovigilance reporting to MOHAP follows the GCC ADR template with 15-day expedited timelines for serious unexpected reactions.
- UAE-format CTD with Arabic Module 1 prepared
- WHO-GMP plant inspection report shareable on request
- CoPP, manufacturing licence and free-sale certificate (legalized)
- Bioequivalence study vs. EU reference product on file
- ISO code
AE· trade currency UAE Dirham (AED)